SCHEDULE 13G/A 0001841619 XXXXXXXX LIVE 6 Common Stock, par value $0.0001 per share 09/30/2025 0001343009 CNBX Pharmaceuticals Inc. 13764M209 #3 Bethesda Metro Center, Suite 700 Bethesda MD 20814 Rule 13d-1(c) 3i, LP a DE 0.00 80865244.00 0.00 80865244.00 80865244.00 N 9.9 PN As more fully described in Item 4 of this Amendment No. 6 to Statement on Schedule 13G (''Amendment No. 6''), such shares and percentage are based on 753,196,666 shares of common stock, par value $0.0001 per share, of the issuer (the ''Common Stock'') outstanding as of September 30, 2025, as verified with the issuer. Beneficial ownership consists of 24,600,000 shares of Common Stock held directly by the reporting person and 56,265,244 shares of Common Stock issuable upon conversion of a senior secured convertible note (the ''Note'') held directly by the reporting person, which conversion is subject to a 9.99% beneficial ownership limitation provision (the ''Blocker''). 3i Management LLC a DE 0.00 80865244.00 0.00 80865244.00 80865244.00 N 9.9 OO As more fully described in Item 4 of this Amendment No. 6, such shares and percentage are based on 753,196,666 shares of Common Stock outstanding as of September 30, 2025, as verified with the issuer. Beneficial ownership consists of 24,600,000 shares of Common Stock held indirectly by the reporting person and 56,265,244 shares of Common Stock issuable upon conversion of the Note held indirectly by the reporting person, which conversion is subject to a 9.99% Blocker. Maier Joshua Tarlow a X1 0.00 80865244.00 0.00 80865244.00 80865244.00 N 9.9 IN As more fully described in Item 4 of this Amendment No. 6, such shares and percentage are based on 753,196,666 shares of Common Stock outstanding as September 30, 2025, as verified with the issuer. Beneficial ownership consists of 24,600,000 shares of Common Stock held indirectly by the reporting person and 56,265,244 shares of Common Stock issuable upon conversion of the Note held indirectly by the reporting person, which conversion is subject to a 9.99% Blocker. CNBX Pharmaceuticals Inc. #3 Bethesda Metro Center, Suite 700, Bethesda, MD 20814 (i) 3i, LP, a Delaware limited partnership ("3i"); (ii) 3i Management LLC, a Delaware limited liability company ("3i Management''); and (iii) Maier Joshua Tarlow ("Mr. Tarlow"). The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons". Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 1 to the Statement on Schedule 13G filed by the Reporting Persons with the SEC on March 6, 2023 (the "Schedule 13G"), as amended by Amendment No. 1 to Schedule 13G filed by the Reporting Persons with the SEC on February 13, 2024 ("Amendment No. 1"), as amended by Amendment No. 2 to Schedule 13G filed by the Reporting Persons with the SEC on November 14, 2024 ("Amendment No. 2"), as amended by Amendment No. 3 to Schedule 13G filed by the Reporting Persons with the SEC on February 13, 2025 ("Amendment No. 3"), as amended by Amendment No. 4 to Schedule 13G filed by the Reporting Persons with the SEC on May 13, 2025 ("Amendment No. 4"), as amended by Amendment No. 5 to Schedule 13G filed by the Reporting Persons with the SEC on August 13, 2025 ("Amendment No. 5 and together with Amendment No. 1, Amendment No. 2, Amendment No. 3, and Amendment No. 4, the "Amendments"), pursuant to which the Reporting Persons have agreed to file this Amendment No. 6 and all subsequent amendments to this Amendment No. 6, the Schedule 13G and the Amendments jointly in accordance with the provisions of Rule 13d-1(k) of the Act. The filing of this Amendment No. 6 should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of Common Stock reported herein. 2 Wooster Street, 2nd Floor, New York, NY 10013. 3i is a Delaware limited partnership. 3i Management is a Delaware limited liability company. Mr. Tarlow is a citizen of the United States. Y The purpose of this Amendment No. 6 is to amend and supplement the Schedule 13G and the Amendments in order to update the beneficial ownership information on the cover pages and in Item 4 in the Schedule 13G and in the Amendments. The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Amendment No. 6 and is incorporated herein by reference for each such Reporting Person. The share amounts and ownership percentages reported are based on 753,196,666 shares of Common Stock outstanding as of September 30, 2025, as verified with the issuer. 3i holds (i) 24,600,000 shares of Common Stock and (ii) the Note in the principal amount of approximately $663,924, which is convertible into up to 56,265,244 shares of Common Stock, assuming conversion at the alternate conversion price of the Note as of September 30, 2025, as a result of the triggering of the 9.99% Blocker contained in the Note, which prohibits 3i from converting the Note for shares of Common Stock if, as a result of such conversion, the holder thereof, together with its affiliates and any persons acting as a group together with such holder or any of such affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to such conversion. Consequently, 3i is the beneficial owner of 80,865,244 shares of Common Stock (the "Shares"). 3i is the beneficial owner of the Shares and has the power to dispose of and the power to vote the Shares beneficially owned by it, which power may be exercised by 3i Management, the manager and general partner of 3i. Mr. Tarlow, as the manager of 3i Management, has shared power to vote and/or dispose of the Shares beneficially owned by each of 3i and 3i Management. Mr. Tarlow does not directly own the Shares. By reason of the provisions of Rule 13d-3 of the Act, Mr. Tarlow may be deemed to beneficially own the Shares beneficially owned by 3i and 3i Management, and 3i Management may be deemed to beneficially own the Shares beneficially owned by 3i. 9.99% (A) 3i: 0.00 (B) 3i Management: 0.00 (C) Mr. Tarlow: 0.00 (A) 3i: 80,865,244.00 (B) 3i Management: 80,865,244.00 (C) Mr. Tarlow: 80,865,244.00 (A) 3i: 0.00 (B) 3i Management: 0.00 (C) Mr. Tarlow: 0.00 (A) 3i: 80,865,244.00 (B) 3i Management: 80,865,244.00 (C) Mr. Tarlow: 80,865,244.00 Y Y Y N See Exhibit 1 filed with the Schedule 13G. Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. 3i, LP /s/ 3i, LP 11/10/2025 3i Management LLC /s/ 3i Management LLC 11/10/2025 Maier Joshua Tarlow /s/ Maier Joshua Tarlow 11/10/2025 LIST OF EXHIBITS Exhibit No. 1 - Joint Filing Agreement, dated March 6, 2023 (incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons with the SEC on March 6, 2023).